<DOC>
	<DOCNO>NCT00828789</DOCNO>
	<brief_summary>The purpose study determine effect EFV ( Efavirenz ) TDF ( Tenofovir disoproxil fumarate ) pharmacokinetics TVR ( Telaprevir ) determine effect TVR pharmacokinetics EFV TDF . Pharmacokinetics mean drug absorb bloodstream , distribute body eliminate body . Furthermore , short-term safety tolerability give TVR , EFV TDF together evaluate .</brief_summary>
	<brief_title>VX-950-TiDP24-C134 : Drug-drug Interaction Trial Between Combination Efavirenz Tenofovir Disoproxil Fumarate Different Dosages Telaprevir Healthy Volunteer</brief_title>
	<detailed_description>The trial enroll 20 Healthy volunteer . All participant receive 4 different treatment : Treatment A : TVR every 8 hour alone 6 day additional morning intake Day 7 . Treatment B : EFV + TDF daily alone 7 day . Treatment C : TVR every 8 hour + EFV daily + TDF daily 7 day . Treatment D : TVR every 12 hour + EFV daily + TDF daily 7 day . All participant start Treatment A follow 7 8-day washout period . Subsequently , participant start Treatment B . At end Treatment B , participant randomize ( assign one two sequence chance ) continue without washout period Sequence 1 ( Treatment C follow D without washout ) Sequence 2 ( Treatment D follow C without washout ) . Participants thus receive daily EFV TDF total 21 consecutive day , addition 2 different dosage TVR last 14 day . TVR take food , 30 minute start meal . EFV TDF take empty stomach ( 2.5 hour start breakfast ) . Pharmacokinetic profile TVR VRT-127394 ( R-diastereomer TVR ) measure 8 hour intake morning dose Day 7 Treatments A C , 12 hour intake morning dose Day 7 Treatment D. Pharmacokinetic profile EFV tenofovir measure 24 hour intake Day 7 Treatments B , C , D. Safety tolerability evaluation record regular interval throughout trial period . Treatment A : TVR every 8 hour alone 6 day additional morning intake Day 7 . Treatment B : EFV + TDF daily alone 7 day . Treatment C : TVR every 8 hour + EFV daily + TDF daily 7 day . Treatment D : TVR every 12 hour + EFV daily + TDF daily 7 day .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Females postmenopausal ( amenorrheal least 3 year ) , undergone tubal ligation ( permanent birth control method ) , hysterectomy ( total ) , oophorectomy ( bilateral ) Normal weight screen define body mass index ( BMI , weight kg divide square height meter ) 18 30 kg/m2 , extremes include Normal 12lead ECG screen Healthy basis physical examination , medical history , ECG , vital sign , result blood biochemistry , blood coagulation hematology test urinalysis carry screen Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month study screen . No history presence relevant drug food allergy , cardiovascular central nervous system disease , clinically significant pathology , mental disease psychiatric disorder , chronic skin disease , drug abuse Current use prescription medication Regular treatment overthecounter medication Consumption herbal medication dietary supplement A history drug alcohol abuse addiction within 2 year prior dose , positive test alcohol drug Participation clinical study within 2 month 5 half life investigational drug prior screen visit No positive HIV test hepatitis A , B C infection Having history renal disease Male subject female partner pregnant , plan become pregnant study within 90 day last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Tenofovir disproxil fumarate</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>VX-950-C134</keyword>
	<keyword>VX-950-TiDP24-C134</keyword>
	<keyword>HIV Infections</keyword>
</DOC>